Concept of oncolytic virotherapyclinical
|
|
- Nathaniel Sparks
- 5 years ago
- Views:
Transcription
1 Concept of oncolytic virotherapyclinical implementation Simona Donina A. Kirchenstein Institute of Microbiology and Virology, Riga Stradiņš University Riga East University Hospital
2 Timeline of the clinical history of oncolytic viruses Ta-Chiang Liu et al.,nature Clinical Practice Oncology 2007
3 A. Complete regression of Burkitt's lymphoma over 2 weeks in a patient experiencing acute measles infection. B. Complete hematologic response of chronic lymphocytic leukemia following patient vaccination with vaccinia and subsequent virus dissemination. Permission obtained from Elsevier Bluming AZ and Ziegler JL (1971) Lancet 2 and from American Medical Association Hansen RM and Libnoch JA (1978) Arch Intern Med Nature Clinical Practice Oncology 2007
4 Advantages of oncolytic virotherapy L Braidwood et al., Oncolytic Virotherapy 2013:2 Feature Replicates within tumor cells to increase viral dose Replicates only within tumor cells Can be used safely with other cancer treatments and may have synergistic effect Can also be engineered or armed to carry a wide variety of transgenes to enhance the therapeutic effect such as prodrugs or inducers of immunological response Some evidence that ohsv are capable of targeting and eliminating cancer stem cells Advantage Amplification leads to oncolysis in cells beyond those initially infected Increases therapeutic index Minimal toxicity to normal tissues Dual effect of viral oncolysis and the added effect of the prodrug or immune stimulator Eliminates the population of cells that are often resistant to chemotherapy and radiotherapy
5 Infection and killing of tumor cells by oncolytic viruses Selective targeting to tumor cells innate properties of native viral particles engineered viruses through deletion of nonessential viral genes or insertion of tumor targeting sequences to provide the virus with the property of tumor-selective infection Ability to induce tumor cell lysis Induction of local and systemic antitumor immune respons expression of viral proteins and release of antigens eventually also leads to immune-mediated lysis of infected cells by CD8 + cells. T Hughes et al, Oncolytic Virotherapy 2014
6 Infection and killing of tumor cells by oncolytic viruses L Aurelian et al., Oncolytic Virotherapy 2013 Increased binding to altered target Replication/intratumoral spread Cell lysis/antigen release/immune response/virus spread Reduced target binding Virus does not replicate Healthy tissue undamaged
7 The immune response to oncolytic virotherapy is an essential factor determining the success of virus as an antitumor agent NK B Mf Tc Th
8 Hypothesis... During the virotherapy downregulate early innate immune response in order to allow the virus longer to enter cells and undergo initial viral replication upregulate later cellular immune response to make infected tumor cells more likely targeted for destruction by immune system L Aurelian et al., Oncolytic Virotherapy 2013
9 The oncolytic virotherapy paradigm
10 Barriers to optimal delivery of oncolytic viruses to tumours in vivo Kelley A et al., Nature Reviews Cancer 2005
11 Challenges Bazan-Peregrino M, et al., J Control Release Miller CG et al., Mol Ther Benencia F et al., Hum Gene Ther J Goldufsky et al, Oncolytic virotherapy 2014 Increasing the replicative capacity of the virus within cancer cells Alteration of the microenvironment (inhibition of angiogenesis) Combination with chemo- and immunotherapy Avoidance of neutralizing antibodies
12 April 14, 2010 Biovex OncoVEX(gm-csf) uses a highly potent oncolytic virus that replicates selectively in tumors and do not replicate in normal cells), destroying cancer cells while leaving surrounding healthy cells unharmed
13 Talimogene laherparepvec (T-VEC) The drug was initially developed by BioVex, Inc. under the name OncoVEX GM-CSF until it was acquired by Amgen in T-VEC was engineered from herpes simplex virus A number of genetic modifications (deletion in both copies of ICP ICP47 disruption) were made to the virus in order to: attenuate the virus ( it can no longer cause herpes) increase selectivity for cancer cells ( it destroys cancer cells while leaving healthy cells unharmed) secrete the cytokine GM-CSF
14 T-VEC Kaufman HL et al., Ann Surg Oncol. 2010;17(3): Núñez MA et al., 2013.
15
16 Amgen announced the initial results of the Phase III OPTiM trial on Mar. 19, The objective response rate (any response) with T- VEC was 26%, (11% CR) The most common side effects with T-VEC were fatigue, chills, and fever. No serious side effect occurred in more than 3% of patients in either arm of the study.
17
18 Feb. 5, 2014 Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma About Talimogene Laherparepvec Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumor tissue and to initiate a systemic anti-tumor immune response. Talimogene laherparepvec is injected directly into tumor tissue and is intended to replicate preferentially in tumor cells causing lytic cell death and releasing an array of tumor-derived antigens. Talimogene laherparepvec is also engineered to express granulocyte-macrophage colonystimulating factor (GM-CSF),which can help to activate the immune system. The aim of this combination of actions is to initiate a systemic anti-tumor immune response that targets tumor cells throughout the body. About MK-3475 Many tumors are able to evade the immune system through a mechanism that exploits the PD-1 inhibitory checkpoint protein. MK-3475 is an investigational, highly selective anti-pd-1 immunotherapy designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation of the immune system's T-cells that target cancer by essentially releasing a brake on the immune system.
19
20 Viralytics trial shows Cavatak well-tolerated 12 November, 2012 Cavatak is a proprietary formulation of coxsackievirus A21, is a naturally occurring common cold like virus shown in pre-clinical studies to stimulate in vitro and in vivo oncolytic activity across a range of cancers. The virus achieves this by binding to the N-terminal domain of surface expressed ICAM-1 which is present on the surface of cancers including melanoma, breast and prostate cancers triggering cytosis in the cells. The results of the phase I trial fulfilled the criteria required for Viralytics to advance to a phase II trial under its IND application for the treatment with the US FDA. Viralytics revealed it has so far dosed 13 patients in the phase II melanoma trial, with three of these demonstrating immune-related progression free survival at six months. The primary objective of the trial is progression-free survival in of a targeted 63 melanoma patients. Viralytics also holds the patents to EVATAK, its proprietary formulation of Echovirus Type 1 (EV1). EVI uses a different cell surface receptor to bind and infect cancer cells.
21
22 In Latvia «Oncotropism of Viruses and the Problem of Virotherapy of Malignant Tumours» by A. Muceniece published in Riga in 1972
23 Viral Oncolysis in a Model of Mouse Xenografts of Human Angiosarcoma (R. Bruvere 1968) Control 2 days after virus i/m 3 days after virus i/m 4 days after virus i/m 9 days after virus i/m
24 Late Alterations in Melanoma Tissue (R. Bruvere 1969) Before therapy Subcutaneous mts of MM 3 months after therapy with Rigvir (apoptotic tumour cells, lymphocytes, plasma cells)
25 Antibody to Rigvir during the therapy (A. Volrate, R. Garklava 1968)
26 Rigvir ECHO-7 containing medicine for treatment of malignant melanoma was registered in 2004 in Latvia
27 Patients (%) with elevated number of CD16+ cells during the therapy with Rigvir 1 Month 3 Months 6 Months 12 Months Pts (n)
28 Patients (%) with elevated number of CD8+ cells during the therapy with Rigvir Pts (n)
29 Patients (%) with elevated number of CD38+ cells during the therapy with Rigvir 1 Month 3 Months 6 Months 12 Months Pts (n)
30 CD 3+ between malignant melanocytes CD8+ in the lymph node after injections of Rigvir IHC after injection of Rigvir (l/n, Dako, 400х 23/05/2013).
31 Vacuolisation and picnosis of nuclei of malignant melanocytes. H/E. 400x
32
33 Female, 62 Melanoma cutis femoris dxt. T4 A N0 M0 Clark V, Breslow 9mm кол-о no. иммуннокомпетентных of immunocompetent cells клеток Ly перeд Rigvir 1 месяц 3 месяца 6 месяцев 12 месяцев Ly CD CD CD CD CD CD CD CD3+ CD4+ CD95+ CD8+ CD38+ CD16+ CD19+
34
35 Before the therapy with RIGVIR Melanoma cutis dorsi T4b N2c M0 During the therapy with RIGV IFN Feb 14, 2008 Apr 29, 2010 RIGVIR
36 Male, Melanoma cutis dorsi T4b N2c M0
37 Melanoma cell culture (patient A.S.) D. Pjanova et col Control 24 and 48 h Rigvir 24 and 48 h
38 Cell viability 24h and 48h after treatment with Rigvir MTT - (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test (p<0.05) D. Pjanova et col. 2014
39 Predictive markers? Immune monitoring?
40 Months Rigvir Observation p=0.001 (Log-Rank test)
41 Summary Oncolytic virus therapy has been well tolerated, with largely minor and expected toxicity, and no evidence of uncontrolled or latent infection. A number of clinical trials have combined oncolytic viruses with a second form of therapy. Further investigation will need to focus on optimal selection of viruses, tumor types and stages of disease, viral dose and schedules, routes of delivery. Our data suggest that ECHO-7 containing medicine- Rigvir- is well tolerated and no remarkable side-effects were documented, and significantly better relapse free suvival for stage IB - IIA patients was observed in Rigvir treated group in our retrospective study.
42
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationOncolytic viruses for cancer treatment
Oncolytic viruses for cancer treatment Interdisciplinary Technical Journal Club: Special Series on Laboratory Animal Science Dr. Katrin Frauenknecht Institute of Neuropathology University Hospital Zurich
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationIMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018
NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements
More informationTalimogene Laherparepvec (T-VEC) at the SCCA: an update
Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science
More informationImmuno-Oncology Clinical Trials Update: Oncolytic Viruses Issue 5 February 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Oncolytic Viruses Issue 5 February 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY series is
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationOncolytic virus strategy
Oncolytic viruses Oncolytic virus strategy normal tumor NO replication replication survival lysis Oncolytic virus strategy Mechanisms of tumor selectivity of several, some of them naturally, oncolytic
More informationREQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC
REQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC The Cancer Therapy Evaluation Program (CTEP) is accepting Project Team Member Applications (PTMAs)
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationTwo roads for oncolytic immunotherapy development
Kaufman and Bommareddy Journal for ImmunoTherapy of Cancer (2019) 7:26 https://doi.org/10.1186/s40425-019-0515-2 COMMENTARY Two roads for oncolytic immunotherapy development Howard L. Kaufman 1,2* and
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationViruses and cancer: Should we be more afraid?
Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development
More informationCoxsackievirus A21 as an oncolytic agent for the control of human cancer
Coxsackievirus A21 as an oncolytic agent for the control of human cancer Dr Gough G. Au PhD Conjoint Research Fellow The University of Newcastle Australia Viralytics Ltd. Viruses can be used to treat cancer
More informationDiscover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15
Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Immunology in cancer The role of immunology in cancer Evolving knowledge of the immune system has provided a better understanding of
More informationPhase 1b KEYNOTE-200 (STORM):
Phase 1b KEYNOTE-2 (STORM): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients Hardev S. Pandha 1, Kevin J. Harrington
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationBrave New World of Cancer Therapeutics (Back to the Future)
Brave New World of Cancer Therapeutics (Back to the Future) Alexandra M. Levine, MD, MACP Chief Medical Officer Melinda & Norman Payson Professor of Medicine Professor of Hematology/HCT City of Hope National
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationExperimental Therapeutics I
Experimental Therapeutics I Mary Hitt 5142 Katz Group Centre mhitt@ualberta.ca; or Mary.Hitt@albertahealthservices.ca 1 Specific Topics for Today Preclinical and clinical testing Gene therapy Nonviral
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationMelanoma. Tawnya L. Bowles, MD Surgical Oncologist, Medical Director for Melanoma Services; Intermountain Medical Center
Melanoma Tawnya L. Bowles, MD Surgical Oncologist, Medical Director for Melanoma Services; Intermountain Medical Center Ken Grossmann, MD, PhD Assistant Professor, Department of Medicine, Oncology Division;
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationDisclosures Information Brendan D. Curti, MD
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy
More informationOncolytic Virotherapy: Targeting Cancer Stem Cells
Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationOncolytic viruses for cancer treatment
2009 3 4 1 Journal of Microbes and Infection, March 2009, Vol. 4, No. 1 35,, 200040 :,, : ; ; Oncolytic viruses for cancer treatment HOU Jian-Gang, DING Qiang Department of Urology, Huashan Hospital, Fudan
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationViruses. Rotavirus (causes stomach flu) HIV virus
Viruses Rotavirus (causes stomach flu) HIV virus What is a virus? A virus is a microscopic, infectious agent that may infect any type of living cell. Viruses must infect living cells in order to make more
More informationIMMUNOTHERAPY IMMUNOTHERAPY. BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference 2 Safe harbor Any statements contained herein that
More informationTHE IMLYGIC STORY: A WINDING PATH TO INNOVATION
THE IMLYGIC STORY: A WINDING PATH TO INNOVATION EBE Workshop EU CASSS 22 May 2017 MICHAEL ABERNATHY EXECUTIVE DIRECTOR, RA CMC WHY DO WE INNOVATE? Today, one of these children has Stage IV pancreatic cancer
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationPoster No: 319. Dr Nicola Annels University of Surrey, UK
Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non- Muscle Invasive Bladder (NMIBC) Cancer using Intravesical Coxsackievirus A21. Poster No: 319 Dr Nicola Annels University of Surrey,
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationViewpoint from a health care professional
Viewpoint from a health care professional Christoph Hoeller Skin Cancer Center at the Department of Dermatology Medical University of Vienna Austria Certified Skin Tumor Center The fifth annual regulatory
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationEBV infection B cells and lymphomagenesis. Sridhar Chaganti
EBV infection B cells and lymphomagenesis Sridhar Chaganti How EBV infects B-cells How viral genes influence the infected B cell Differences and similarities between in vitro and in vivo infection How
More informationCoxsackievirus A21: The basic facts
Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationConnections Between Autoimmune Disease & Cancer
February 6, 2018 Connections Between Autoimmune Disease & Cancer Dr. Reetesh Bose, PGY2 Supervisor: Dr. Jennifer Beecker, MD, CCFP(EM), FRCPC, DABD, FAAD University of Ottawa, Division of Dermatology Definitions
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationPD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs
PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium
More informationKey Points of Mistletoe Therapy. Robbin Coedy B.Sc., M.Sc.
Key Points of Mistletoe Therapy Robbin Coedy B.Sc., M.Sc. Basic Rules of Mistletoe Therapy 1) Inject in the abdomen (preferred), thigh or upper arm 2) Most protocols are 3x/week 3) Start at a low dose
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationMetastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds
Metastatic Melanoma Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds Case Presentation 77 year old male with previous history of scalp melanoma and thyroid
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationTG4010. Public Information
TG4010 Public Information 11 May 2017 Public Information 11 May 2017 Page 2 /7 ABBREVIATIONS DNA Deoxyribonucleic acid GMO Genetically modified organism IL2 Interleukin-2 IM Intramuscular IT Intratumoral
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More information2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s
MEETING REPORT: 2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s www.immuno-oncologysummit.com By Cole Peters and Fares Nigim, M.D. from Mass General Hospital - Harvard Medical School Cambridge Healthtech
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationA Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus 1 Mutant rrp450 in Patients with Refractory Sarcoma or Neuroblastoma
A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus 1 Mutant rrp450 in Patients with Refractory Sarcoma or Neuroblastoma Timothy P. Cripe, M.D., Ph.D. Associate Professor Division of Hematology/Oncology
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationNatural Killer (NK) cells and Programmed cell death protein-1 (PD-1)
Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Sujan Badal, MS2; Zachary B. Davis, PhD; Jeffrey Miller, MD Department of Medicine, Division of Hematology, Oncology, and Transplantation
More informationThe Immune System: The Mind Body Connection. Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco
The Immune System: The Mind Body Connection Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco Psychoneuroimmunology Investigation of the bidirectional
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationCurrent State of Immunotherapy for Metastatic Melanoma
Current State of Immunotherapy for Metastatic Melanoma Background: The Duval County Medical Society (DCMS) is proud to provide its members with free continuing medical education (CME) opportunities in
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationParallels between cancer and infectious disease
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Parallels between cancer and infectious disease Richard S. Hotchkiss Washington University School of Medicine
More informationRigvir great potential in struggle against the cancer
TOPIC virus Rigvir great potential in struggle against the cancer The positive impact of viruses has been discovered in Riga, Latvia long time ago. They successfully work with a special virus called Rigvir
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More information2010 ASCO Annual Meeting Chicago, IL June 4 - June 8, 2010
2010 ASCO Annual Meeting Chicago, IL June 4 - June 8, 2010 Abstract ID: 2546 Poster Board #: 1H A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol
More informationLYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS
LYMPHOCYTES & IMMUNOGLOBULINS Dr Mere Kende, Lecturer SMHS Immunity Immune- protection against dangers of non-self/invader eg organism 3 components of immune system 1 st line: skin/mucosa/cilia/hair/saliva/fatty
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationEnhancing Anti-tumour Immunity with Oncolytic Viruses
Enhancing Anti-tumour Immunity with Oncolytic Viruses John Bell Ottawa Hospital Research Institute SUPPORTED BY: NATIONAL CANCER INSTITUTE OF CANADA/CCS THE TERRY FOX FOUNDATION PPG CANADIAN INSTITUTES
More informationInnovative Combination Strategies: Oncolytic and Systemic Therapy
Innovative Combination Strategies: Oncolytic and Systemic Therapy Sanjiv S. Agarwala, MD Professor of Medicine, Temple University Chief, Oncology & Hematology St. Luke s Cancer Center Bethlehem, PA, USA
More information